Leave Your Message

Dabrafenib Daawaynta Bartilmaameedsan ee Kansarka BRAF-Is-beddelay

Qiimaha Dabiiciga ah: USD 50-60 / kg

  • Magaca Alaabta Dabrafenib
  • CAS Maya. 1195765-45-7
  • MF C23H20F3N5O2S2
  • MW 519.561
  • EINECS 1592732-453-0
  • Cufnaanta 1.443
  • Barta karkarinta 653.726 °C at 760 mmHg

Sharaxaad faahfaahsan

Dabrafenib waa caabiyaha afka laga heli karo ee borotiinka B-raf (BRAF) waxaana loo isticmaalaa dawo ka hortagga kansarka. Waxay si xushmad leh u bartilmaameedsanaysaa kansarrada la xidhiidha nooca beddelmay ee hidda-wadaha BRAF. Maqaalkani wuxuu sahamiyaa habka ficilka, calaamadaha bukaan-socodka, iyo isticmaalka dabrafenib ee daaweynta kansarrada kala duwan.

I. Fahamka Dabrafenib:
A. Joojiyaha borotiinka B-raf (BRAF).
B. Habka ficilka: Joojinta calaamadaynta borotiinka ee aan caadiga ahayn iyo nidaaminta koritaanka unugyada

17159473034104h3

II. Tilmaamaha Caafimaadka:

A. monotherapy:

Melanoma aan la daboolin ama metastatic oo leh isbeddel BRAF V600E

B. Daaweynta isku dhafka ah ee trametinib:

BRAF V600E-togan oo aan la dabar goyn ama melanoma metastatic

Metastatic kansarka sanbabada unug yar oo aan yarayn

Metastatic anaplastic kansarka qanjirka thyroid

Burooyinka adag ee aan la soo saari karin ama metastatic


III. Habka Waxqabadka:

A. Xulashada xidhitaanka iyo ka hortagga B-raf

B. Joojinta kororka unugyada burooyinka oo leh hiddo-wade BRAF oo isbedelay


IV. Daaweynta Kansarka Thyroid:

A. Nooc ka mid ah kansarka tayroodhka oo ku faafay unugyada u dhow ama qaybaha kale ee jidhka

B. Daaweyntii hore ee caabbinta


V. Kinase Inhibitor Class:

A. Dabrafenib oo xubin ka ah kinase inhibitors

B. Joojinta ficilka borotiinka ee aan caadiga ahayn si looga hortago isku dhufashada unugyada kansarka


Dabrafenib waa daawayn la beegsaday oo loo isticmaalo daawaynta kansarrada BRAF-is-beddelay. Sida horjoogaha borotiinka B-raf (BRAF), waxay si xushmad leh u bartilmaameedsataa unugyada burooyinka ee ay ku jiraan hidda-wadaha BRAF ee is-beddelay, taas oo ka hortagaysa faafitaankooda. Dabrafenib waxaa lagu tilmaamaa melanoma aan la sixi karin ama metastatic melanoma, kansarka sambabada unugyada aan yareyn, kansarka tayroodhka anaplastic, iyo burooyin adag oo aan la sixi karin ama metastatic. Daaweynta isku dhafka ah ee trametinib waxay sii ballaarineysaa codsigeeda. Marka la fahmo isbeddellada hidde-sidaha gaarka ah ee unugyada kansarka, daawaynta la beegsaday sida dabrafenib ayaa door muhiim ah ka ciyaara hagaajinta natiijooyinka daaweynta iyo joojinta faafitaanka unugyada kansarka.

Tilmaamid

1715947563669qd1